WebIMpower 133研究在今年世界肺癌大会上公布结果,并同步发表在《新英格兰医学杂志》(New England Journal of Medicine,NEJM)上。 ... 化疗方案一线治疗ED-SCLC可以改善患者的中位总生存期(median overall survival,mOS)和中位无进展生存期(median progression-free survival,mPFS),给ED-SCLC的治疗 ... Web30 Oct 2024 · In one study (IMpower 133), the immunotherapy drug Tecentriq (atezolizumab) was added to the chemotherapy drugs Paraplatin and VePesid. ... Paz …
The IMpower133 Trial in Extensive-Stage SCLC - Cancer Network
Web1 Oct 2024 · IMpower 133 was a double-blind phase III study in which 403 patients with untreated, extensive-stage SCLC patients and an Eastern Cooperative Oncology Group … Web31 Jan 2024 · The latest data from the IMpower 133 trial shows that maintenance therapy with atezolizumab (Tecentriq) plus carboplatin and etoposide (CP/ET) improves overall … how to use scented gel beads
Chemo-immunotherapy as first-line treatment for small-cell lung …
Web13 Feb 2024 · In the IMPower 133 trial 3, the efficacy of atezolizumab in combination with carboplatin and etoposide was assessed in patients with ES-SCLC. In this phase III, … Web28 Sep 2024 · The patients enrolled in the IMpower133 [trial] were treatment-naive patients with newly diagnosed ES-SCLC. Patients with treated asymptomatic brain metastases … Web5 Jun 2024 · The life expectancy of extensive-stage small cell lung (ES-SCLC) cancer patients has not improved in the last 2–3 decades until two recent trials (CASPIAN and … how to use scented wax melts